Spanish Business Awards 2026 Most Pioneering Disruptive Biotech Company 2026 Based in Madrid, DISIT Biotech is striving to set the standard for innovative therapies for patients with high unmet medical needs. The company was founded in 2020, built upon the core values of patient-centricity, disruptive innovation, and close collaboration with researchers and partners. Driven by these integral values and a steadfast mission, the biotech SME is dedicated to discovering and developing new medicines, integrating biology, chemistry, and translational science to derisk innovative programmes and move them closer to the clinic. “Our values have not changed since our establishment; they are the reason the company was founded,” Rafael told us. “What has evolved is our scale, our capabilities, and the sophistication of our projects, but the core principles remain the same. They are captured in our motto: ‘Let’s work to make it happen. Let’s make it happen together.’ This is both a promise and a way of working: we bring patients, scientists, and partners around the same table, align on a shared vision, and do everything necessary to turn disruptive science into real medicines.” “We bring patients, scientists, and partners around the same table, align on a shared mission, and do everything necessary to turn disruptive science into real medicines.” In a competitive landscape, DISIT Biotech stands out for its focus on derisking projects that competitors will not. Fuelled by the knowledge that only one in 14,000 compounds reach the market, DISIT Biotech deliberately concentrates on scientifically solid R&D that had been stopped for non-scientific or strategic reasons. The company reinterrogates the data, applies new biomarkers, analytics, and patient stratification strategies, and redesigns development paths to unlock value and reduce risk. With a base in Spain and a newly established hub in the Boston-Cambridge ecosystem, It is estimated that only one in 14,000 compounds reach the market, which speaks to the true rarity of successful drug development. Though researchers around the world are eager to bring life-changing innovations to the patients who need them, the unfortunate reality is that approximately 90% of clinical drug development is abandoned before a product can ever reach the market. While each unsuccessful trial can be disappointing to researchers, it is much more detrimental to the patients living with high unmet medical needs, who are waiting desperately for better options. Enter DISIT Biotech, a pioneering company setting out to turn abandoned science into real therapies. We heard more from CoFounder and President of the Board, Rafael González. DISIT Biotech proudly bridges the gap between European and American innovation, accessing principal biotech markets on both sides of the Atlantic. In recent years, Europe has progressively lost ground in earlystage drug development, as preclinical and translational R&D has been deprioritised, causing thousands of biotech companies to disappear before ever validating their science. “In a world where only about one in 14,000 compounds reaches the market, removing support at this stage is simply not compatible with a serious commitment to patients and innovation,” stated Rafael González. “This is why, as a pioneering and disruptive Spanish biotech, we see our presence in the US – particularly in the Boston-Cambridge hub – not as something ‘nice to have’ but as an obligation. If we are serious about our patients, we must operate where capital, partners, and decision-makers are most active, and where the bar is highest.” Establishing itself in both European and American markets has had a significant impact on DISIT Biotech’s work, forcing the company to compete within the world’s most dynamic and challenging biotech space. This dual footprint increases the probability that programmes will actually reach patients and enables DISIT Biotech to showcase the best of Spanish science on a truly global stage. “In that sense,” Rafael added, “we embody what we believe the next generation of Spanish business should be: rooted locally, competing globally.” With an expansive market reach and a mission to transform both new discoveries and high-quality, abandoned R&D into tangible therapies, DISIT Biotech collaborates with a wide range of industry partners. This includes biotechnology and pharmaceutical companies, academic groups, hospitals, and research consortia, all relying on the company’s platform, scientific expertise, and ability to turn bold ideas into reliable drug candidates. The team works hand-in-hand with these partners, sharing data and decisions with the sole priority of patient impact in mind. Partners of DISIT Biotech benefit from the company’s dedication to derisking projects both scientifically and from a business and investment standpoint, while Contact: Rafael Gonzalez Company: DISIT Biotech Web Address: www.disitbiotech.com
RkJQdWJsaXNoZXIy MTUyMDQwMA==